ArticleBioscience reports2020
Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases.
Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Diagnostic and prognostic value of circulating microRNA-21 in heart failure: A systematic review and meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- A meta-analysis of microRNA expression profiling studies in heart failure.Heart failure reviews · 2021Pooled it
- Exploration of Potential Genetic Biomarkers for Heart Failure: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Circulating miR-126 and miR-155 are associated with environmental lead exposure: A translational approach via human biomonitoring and bioinformatic networks.Toxicology reports · 2026Article
- MicroRNA profile in normal pregnancies with isolated low IgM anticardiolipin levels.Reproduction & fertility · 2026Article
- Interpretation of the molecular mechanism and therapeutic potential of microRNA‑155 in cardiovascular and cerebrovascular diseases (Review).International journal of molecular medicine · 2026Review
- The Role of microRNA-19b, microRNA-21, and microRNA-208a in diagnosis of heart failure.BMC cardiovascular disorders · 2025Article
- Preliminary identification of the MiR-548ah-5p/THBD axis for heart failure via DirectTarget causal framework and bioinformatics analysis.European journal of medical research · 2025Article
- Review
- The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- The association of serum hsa-miR-21-5p expression with the severity and prognosis of heart failure with reduced ejection fraction.BMC cardiovascular disorders · 2025Article
- Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study.Frontiers in cardiovascular medicine · 2025Article
- Extracellular Vesicle-Derived Non-Coding RNAs: Key Mediators in Remodelling Heart Failure.Current issues in molecular biology · 2024Review
- Exosomal miRNA-21-5p and miRNA-21-3p as key biomarkers of myocardial infarction.Health science reports · 2024Article
- Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review.Cardiac failure review · 2024Review
- Ginsenoside Rb2 improves heart failure by down-regulating miR-216a-5p to promote autophagy and inhibit apoptosis and oxidative stress.Journal of applied biomedicine · 2023Article
- A cellular regulator of the niche: telocyte.Tissue barriers · 2023Review
- MicroRNA-216a is essential for cardiac angiogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- MicroRNAs: diagnostic, prognostic and therapeutic role in heart failure-a review.ESC heart failure · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of circulating microRNAs as biomarkers opens up new opportunities for the diagnosis of cardiovascular diseases because of their specific expression profiles. The aim of the present study was to identify circulating microRNAs in human plasma as potential biomarkers of heart failure and related diseases. We used real-time quantitative PCR to screen microRNA in plasma samples from 62 normal controls and 62 heart failure samples. We found that circulating miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 expressed differently between healthy controls and heart failure patients. Plasma levels of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 were unaffected by hemolysis. Correlation analysis showed any two of these miRNAs possess a strong correlation, indicating a possibility of combined analysis. MiR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 could be combined in two or three or more combinations. The results suggest that miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 may be a new diagnostic biomarker for heart failure and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.